Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients
NCT04080843
Colonic Diseases, Colorectal Cancer
Hangzhou, Zhejiang, China
View Trial DetailsNCT Number: NCT01260168
The objective of this study is to confirm the sensitivity of a stool DNA test for detection of colorectal cancer and pre-cancer.
Another objective is to provide anonymous, clinically characterized specimens for a bio-repository for future colorectal cancer-related test development.
Looking for future studies?
Notify Me40 year–90 year
All sexes
Observational
University of Calgary, Calgary, Alberta, Canada
Patients who have been recently diagnosed with colo-rectal cancer or pre-cancer will be asked to submit a stool sample(s)(at least 7 days AFTER colonoscopy) and will have the option of submitting blood and tissue samples for future colo-rectal cancer-related test development.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 12 Months
The diagnostic test under development is a multi-marker stool test for detecting CRC and pre-cancer in a general screening application. The primary objective of this study is to confirm the sensitivity of the optimal DNA marker panel.
Time frame: 12 Months
Residual samples from patients diagnosed with colorectal cancer will be archived for further research intended to help in the diagnosis of cancers. Specimens will be stored up to 10 years in the Sponsor's on-site bio-repository or similar commercial bio-repository contracted by the sponsor.
Exact Sciences Corporation
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04080843
Colonic Diseases, Colorectal Cancer
Hangzhou, Zhejiang, China
View Trial DetailsNCT02503696
Colonic Diseases, Colorectal Cancer
Dothan, Alabama, United States
View Trial DetailsNCT01397747
Colonic Diseases, Colorectal Cancer
Birmingham, Alabama, United States
View Trial DetailsNCT01600209
Colonic Diseases, Colorectal Cancer
Tucson, Arizona, United States
View Trial Details